Immuneering (IMRX) Stock Price, News & Analysis

Company Overview

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. Immuneering also maintains discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications. Through strategic collaborations and licensing partnerships, the company extends the application of its computational platform across multiple therapeutic areas and works alongside pharmaceutical partners to co-develop novel treatments.

Founded in 2016, Immuneering is headquartered in Cambridge, Massachusetts, and operates research facilities in the United States. After completing its initial public offering on the Nasdaq in early 2021, the company has continued to expand its computational infrastructure, diversify its pipeline through in-house research and external collaborations, and advance its mission to bring more effective, AI-driven therapies to patients worldwide.

Key Stats

• Today's Range: $3.90 to $4.18
• 50-Day Range: $3.92 to $6.13
• 52-Week Range: $1.66 to $10.08
• Volume: 1.11 million shs
• Average Volume: 2.24 million shs
• Market Capitalization: $253.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Moderate Buy

Immuneering Stock Analysis - MarketRank™

Immuneering scored higher than 53% of companies evaluated by MarketBeat, and ranked 592nd out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Immuneering has a consensus price target of $16.50, representing about 320.9% upside from its current price of $3.92.

Amount of Analyst Coverage

Immuneering has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immuneering are expected to decrease in the coming year, from ($1.12) to ($1.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immuneering is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immuneering is -3.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immuneering has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

25.51% of the float of Immuneering has been sold short.

Short Interest Ratio / Days to Cover

Immuneering has a short interest ratio ("days to cover") of 4.95.

Change versus previous month

Short interest in Immuneering has recently increased by 28.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immuneering does not currently pay a dividend.

Dividend Growth

Immuneering does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.94

News Sentiment

Immuneering has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Immuneering this week, compared to 3 articles on an average week.

Search Interest

10 people have searched for IMRX on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.

MarketBeat Follows

5 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immuneering insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/10/2026
• AGM 2026: 6/11/2026
• Next Earnings (Estimated): 8/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMRX
• CIK: 1790340
• Web: www.immuneering.com
• Phone: 617-500-8080
• Fax: N/A
• Employees: 60
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Immuneering: $16.50
• High Price Target: $30.00
• Low Price Target: $11.00
• Potential Upside/Downside: +320.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.03 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.93%
• Return on Assets: -29.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 32.45
• Quick Ratio: 32.45

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.38 per share
• Price / Book: 1.16

Miscellaneous

• Outstanding Shares: 64,700,000
• Free Float: 49,881,000
• Market Cap: $253.62 million
• Optionable: Not Optionable
• Beta: 0.38